SMS Lifesciences India Ltd. engages in manufacturing and selling of active pharmaceutical products. The company is headquartered in Hyderabad, Telangana. The company went IPO on 2017-08-17. The firm's products include Ranitidine HCL (Form-2) USP / Ph.Eur, Famotidine USP / Ph. Eur / JP, Itraconazole USP / Ph.Eur / JP, Lanoconazole USP / JP and Sildenafil Citrate USP / Ph.Eur. The firm's manufacturing facilities are located at Kazipally and Jeedimetla, Hyderabad. The firm's wholly owned subsidiary is Mahi Drugs Private limited.
Loading chart…
Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:
The headline call - descriptive label, conviction, and the synthesis behind it.
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Forensic and governance risk pointers, severity-ranked.
Solvency and earnings-quality score.
Quarter-by-quarter earnings-call briefs - what changed and why.